1. In the past few years, many drug trials have been conducted in the field of Alzheimer's disease (AD). While there has been much written (1) (2) (3) (4) (5) (6) (7) (8) (9) in this journal about methodological aspects of these trials --cognitive tests, global function and neuropsychiatric measures, biomarkers and imaging -strategies for recruitment and retention have been largely neglected. In fact, there has been virtually no research on these topics by either academia or industry over the past 20 years, despite the development of many trials. As a result, trials have had unreasonably long periods of recruitment, too many centers but too few patients recruited by each center, and unacceptably high drop-out rates. In order to recruit 400 patients for a trial today, more than 200 centers are needed from the United States, Europe and Asia. Yet substantial variability among centers results in difficulty interpreting trial results; and with the inclusion of imaging and biomarker studies in these trials, variability has increased while at the same time it has become more difficult to recruit and retain subjects in trials.
2. While we may not be able to find a cure for Alzheimer's disease in the near future, one or several drugs presently in trials have shown promise; however, we may not be able to demonstrate efficacy due to issues of recruitment, retention, site-to-site variability and other methodological issues. It is thus incumbent on the scientific community to find solutions to these problems, particularly as the field moves toward treating the disease in its prodromal stages, where these methodological issues will become even more critical. We need to better understand why participants agree or refuse to enter drug trials, and why both primary care physicians and Alzheimer's specialists agree or refuse to involve their patients (10) (11) (12) (13) (14) (15) (16) (17) . We also need to quantify the impact of requiring imaging studies and lumbar punctures on recruitment and retention. With these concerns in mind, an international task force of experts from academia and industry in the United States, European Union and Japan met in San Diego, California on November 2, 2011 to focus on recruitment, retention and other methodological issues related to clinical trials for AD. We present in this JNHA issue the papers presented during this Task 
